WT1 317–327 (HLA-A*01:01)
( TSEKRPFMCAY )
Wilms tumor protein is a protein that is encoded by the WT1 gene on chromosome 11p in humans. WT1 is a tumour suppressor gene associated with the development of Wilms' Tumour, from which it was named. Mutations in exon 7 and 9 of WT1 have been recurrently identified in acute myeloid leukemia and associated with poorer prognosis and chemotherapy resistance. The WT1 peptide is a transcription factor that contains four zinc finger motifs at the C-terminus and a proline / glutamine-rich DNA-binding domain at the N-terminus. It has an essential role in the normal development of the urogenital system. WT1 has been ranked by the National Cancer Institute (NCI) as the Number 1 target for cancer immunotherapy. This gene encodes a transcription factor that contains four zinc-finger motifs at the C-terminus and a proline/glutamine-rich DNA-binding domain at the N-terminus. It has an essential role in the normal development of the urogenital system, and it is mutated in a small subset of patients with Wilms tumor. This gene exhibits complex tissue-specific and polymorphic imprinting pattern, with biallelic, and monoallelic expression from the maternal and paternal alleles in different tissues. Multiple transcript variants have been described.
Sequence: | TSEKRPFMCAY | |
Gene: | WT1 | |
Delivery: | 2-3 days | |
C-Terminus: | OH | |
N-Terminus: | H | |
Amount: | 1 mg | |
Counter Ion: | TFA | |
Protein: | Wilms-Tumor-Protein | |
Species: | Human | |
Allele: | HLA-A*01:01 | |
Application : | Cellular immune response, Immune monitoring, T-cell assays, Immunohistochemistry | |
Indication : | AIDS, Autoimmune disease, Breast cancer, Cancer, Cancer chemotherapy, Control, Diabetes, Graft-vs-host disease, Hematopoetic system, Hepatitis, Infection, Malaria, Malignant genital cancers, Melanoma, Prostate cancer, Testis/ovary cancer, Tuberculosis, Transplantation, Vaccination, Wilms tumor 1Delivery Time: 10-12 daysAIDS, Autoimmune disease, Breast cancer, Cancer, Cancer chemotherapy, Control, Diabetes, Graft-vs-host disease, Hematopoetic system, Hepatitis, Infection, Malaria, Malignant genital cancers, Melanoma, Prostate cancer, Testis/ovary cancer, Tuberculosis, Transplantation, Vaccination, Wilms tumor 1Delivery Time: 10-12 daysAIDS, Autoimmune disease, Breast cancer, Cancer, Cancer chemotherapy, Control, Diabetes, Graft-vs-host disease, Hematopoetic system, Hepatitis, Infection, Malaria, Malignant genital cancers, Melanoma, Prostate cancer, Testis/ovary cancer, Tuberculosis, Transplantation, Vaccination, Wilms tumor 1Delivery Time: 10-12 daysAIDS, Autoimmune disease, Breast cancer, Cancer, Cancer chemotherapy, Control, Diabetes, Graft-vs-host disease, Hematopoetic system, Hepatitis, Infection, Malaria, Malignant genital cancers, Melanoma, Prostate cancer, Testis/ovary cancer, Tuberculosis, Transplantation, Vaccination, Wilms tumor 1Delivery Time: 10-12 daysAIDS, Autoimmune disease, Breast cancer, Cancer, Cancer chemotherapy, Control, Diabetes, Graft-vs-host disease, Hematopoetic system, Hepatitis, Infection, Malaria, Malignant genital cancers, Melanoma, Prostate cancer, Testis/ovary cancer, Tuberculosis, Transplantation, Vaccination, Wilms tumor 1Delivery Time: 10-12 days | |
Purity : | 95% HPLC-MS |
Protocols and Tips
Data sheets
Safety data sheet poly peptides:For your convenience, we have compiled a selection of publications
where our peptide products have been employed:
Publications >
€60.40*
sterile and endotoxin free
Delivery Format: The product is supplied freeze dried.
Purity: 95% HPLC-MS